ADMA Biologics Announces Closing of $69 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
December 09, 2022 16:05 ET
|
ADMA Biologics, Inc.
RAMSEY, N.J. and BOCA RATON, Fla., Dec. 09, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq:ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to...
ADMA Biologics Announces Pricing of Public Offering for $60 Million of Common Stock
December 07, 2022 08:45 ET
|
ADMA Biologics, Inc.
RAMSEY, N.J. and BOCA RATON, Fla., Dec. 07, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq:ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to...
ADMA Biologics Announces Proposed Public Offering of Common Stock
December 06, 2022 16:05 ET
|
ADMA Biologics, Inc.
RAMSEY, N.J. and BOCA RATON, Fla., Dec. 06, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to...
ADMA Biologics Announces Preliminary Fourth Quarter 2022 Revenue Estimate
December 06, 2022 16:01 ET
|
ADMA Biologics, Inc.
RAMSEY, N.J. and BOCA RATON, Fla., Dec. 06, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to...
ADMA Biologics Announces Third Quarter 2022 Financial Results and Provides Business Update
November 09, 2022 16:05 ET
|
ADMA Biologics, Inc.
3Q2022 Total Revenues Were $41.1 Million, a 99% Y-o-Y Increase Grew 3Q2022 Gross Profit to $9.7 Million, a $9.3 Million Y-o-Y Increase Raising FY 2022 Total Revenue Guidance to $145...
ADMA Biologics to Report Third Quarter 2022 Financial Results on November 9, 2022
November 02, 2022 07:00 ET
|
ADMA Biologics, Inc.
Conference Call Scheduled for November 9, 2022, at 4:30 p.m. ET RAMSEY, N.J. and BOCA RATON, Fla., Nov. 02, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”),...
ADMA BioCenters Receives FDA Approval for its Seventh Plasma Collection Center, Located in Greensboro, NC
October 31, 2022 07:00 ET
|
ADMA Biologics, Inc.
FDA Approval Supports Corporate Goal of Plasma Supply Self-Sufficiency and Ongoing Revenue Growth Company Remains On-Track to Have All 10 Plasma Collection Centers FDA-Licensed by Year-End 2023 ...
ADMA Biologics Announces Second Quarter 2022 Financial Results and Provides Business Update
August 10, 2022 16:05 ET
|
ADMA Biologics, Inc.
2Q2022 Total Revenues Were $33.9 Million, a 90% Y-o-Y Increase Grew 2Q2022 Gross Profit to $7.8 Million, Up 112% Over 1Q2022 Narrowed 2Q2022 Net Losses to $13.8 Million, a 45% Improvement Over...
ADMA Biologics to Report Second Quarter 2022 Financial Results on August 10, 2022
August 03, 2022 07:00 ET
|
ADMA Biologics, Inc.
RAMSEY, N.J. and BOCA RATON, Fla., Aug. 03, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to...
ADMA Biologics Announces Addition to the Russell 2000® Index
June 21, 2022 07:00 ET
|
ADMA Biologics, Inc.
Ramsey, N.J. and Boca Raton, Fla., June 21, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to...